Tumors biopsied from women with invasive breast cancer are having their genomes sequenced in an attempt to develop a DNA profile that one day may identify ahead of time the patients who will most likely respond to chemotherapy with an aromatase inhibitor.
Read MorebioTheranostics, a bioMerieux company announces the launch of an expanded tumor-type database for its flagship product, CancerTYPE ID, and the launch of KRAS mutational testing.
Read More
Abbott announced that it has entered into an agreement with GlaxoSmithKline (GSK) to develop a molecular diagnostic test intended for use as an aid in selecting patients who may benefit from a skin cancer treatment in development by GSK.
Read MoreSpecific chemical modifications to proteins called histones, which are found in the nucleus of cells and act as spools around which DNA is wound, can be used to predict prognosis and response to treatment in subsets patients with pancreatic cancer, according to a new study.
Read More